Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLDXNASDAQ:MNKDNASDAQ:MYGNNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDXCelldex Therapeutics$20.35-0.1%$18.91$14.40▼$47.00$1.35B1.39895,300 shs477,438 shsMNKDMannKind$4.12-2.4%$4.75$4.05▼$7.63$1.25B1.142.38 million shs2.03 million shsMYGNMyriad Genetics$3.91-0.5%$7.15$3.81▼$29.30$360.41M2.011.14 million shs1.61 million shsNVAXNovavax$7.25-0.5%$6.62$5.01▼$23.86$1.17B3.217.29 million shs5.57 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDXCelldex Therapeutics-0.10%-0.49%+4.73%-9.39%-46.59%MNKDMannKind-2.37%-5.72%-10.82%-28.53%-14.52%MYGNMyriad Genetics-0.51%-5.33%-46.36%-72.45%-83.70%NVAXNovavax-0.55%+7.73%-3.13%-9.26%-53.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLDXCelldex Therapeutics1.969 of 5 stars4.50.00.00.03.70.00.0MNKDMannKind2.9705 of 5 stars3.61.00.00.03.41.71.9MYGNMyriad Genetics3.9992 of 5 stars4.02.00.04.11.71.70.6NVAXNovavax3.7197 of 5 stars3.21.00.04.73.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDXCelldex Therapeutics 2.90Moderate Buy$53.90164.86% UpsideMNKDMannKind 3.25Buy$10.00142.72% UpsideMYGNMyriad Genetics 2.06Hold$14.79278.15% UpsideNVAXNovavax 2.43Hold$19.00162.07% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, CLDX, MNKD, and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/7/2025MYGNMyriad GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDXCelldex Therapeutics$7.56M178.72N/AN/A$9.08 per share2.24MNKDMannKind$297.60M4.21N/AN/A($0.91) per share-4.53MYGNMyriad Genetics$831.30M0.43N/AN/A$9.53 per share0.41NVAXNovavax$1.21B0.97N/AN/A($6.04) per share-1.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%N/AMNKDMannKind-$11.94M$0.1058.8617.91N/A8.07%-17.74%8.68%8/6/2025 (Estimated)MYGNMyriad Genetics-$263.30M-$1.12N/AN/AN/A-14.09%-4.51%-3.07%8/5/2025 (Estimated)NVAXNovavax-$545.06M$2.65N/A90.632.85-32.18%N/A-17.05%N/ALatest MYGN, CLDX, MNKD, and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million2/27/2025Q4 2024CLDXCelldex Therapeutics-$0.73-$0.71+$0.02-$0.71$1.25 million$1.18 million2/27/2025Q4 2024NVAXNovavax-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million2/26/2025Q4 2024MNKDMannKind$0.03$0.03N/A$0.03$74.99 million$76.78 million2/25/2025Q4 2024MYGNMyriad Genetics$0.03-$0.09-$0.12-$0.47$210.35 million$210.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDXCelldex TherapeuticsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDXCelldex TherapeuticsN/A24.2724.27MNKDMannKindN/A4.544.17MYGNMyriad Genetics0.051.901.73NVAXNovavaxN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDXCelldex TherapeuticsN/AMNKDMannKind49.55%MYGNMyriad Genetics99.02%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipCLDXCelldex Therapeutics3.80%MNKDMannKind2.70%MYGNMyriad Genetics2.10%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableMNKDMannKind400303.93 million267.51 millionOptionableMYGNMyriad Genetics2,60092.18 million89.12 millionOptionableNVAXNovavax1,990161.97 million158.58 millionOptionableMYGN, CLDX, MNKD, and NVAX HeadlinesRecent News About These CompaniesAnalysts Think These Stocks Could More Than Double in Value (NVAX)May 23 at 7:45 AM | marketbeat.comBTIG Maintains a Buy rating on Novavax (NVAX)May 22 at 1:02 PM | insidermonkey.comBofA Reiterates Hold Rating on Novavax (NVAX) StockMay 21 at 4:53 PM | msn.comNovavax: Nuvaxovid FDA Approval Unlocks Several Bullish StimuliMay 21 at 8:35 AM | seekingalpha.comJPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive NewsMay 21 at 3:55 AM | finance.yahoo.comTop Biotech Stocks To Research - May 19thMay 21 at 2:07 AM | americanbankingnews.comFDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks RiseMay 21 at 1:16 AM | msn.comHealthy Returns: Novavax scores narrower Covid vaccine approval after delayMay 20, 2025 | cnbc.comTang Capital Management LLC Sells 400,000 Shares of Novavax, Inc. (NASDAQ:NVAX)May 20, 2025 | marketbeat.comJPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive NewsMay 19, 2025 | insidermonkey.comNovavax’s Nuvaxovid Approval and Market Dynamics Justify Hold Rating Amid Unlocked Pipeline PotentialMay 19, 2025 | tipranks.comNovavax Shares Jump 17% FDA Grants Full Approval to COVID VaccineMay 19, 2025 | gurufocus.comTop Stock Movers Now: Tesla, AutoZone, Novavax, and MoreMay 19, 2025 | investopedia.comNovavax Stock (NVAX) Shoots 15% Higher as Covid Vaccine Jab Gets FDA Green LightMay 19, 2025 | tipranks.comStock Movers Alibaba ADRs, Novavax, RedditMay 19, 2025 | bloomberg.comNVAX Stock Surges on Securing FDA Approval for COVID-19 VaccineMay 19, 2025 | zacks.comNovavax Stock Soars on FDA Approval for COVID VaccineMay 19, 2025 | schaeffersresearch.comNovavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.May 19, 2025 | barrons.comNovavax shares surge 26% after FDA grants conditional approval for Covid vaccineMay 19, 2025 | proactiveinvestors.comNovavax jumps as FDA clears COVID-19 vaccineMay 19, 2025 | seekingalpha.comNovavax’s COVID-19 Vaccine Gains FDA ApprovalMay 19, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYGN, CLDX, MNKD, and NVAX Company DescriptionsCelldex Therapeutics NASDAQ:CLDX$20.35 -0.02 (-0.10%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.34 -0.01 (-0.02%) As of 05/23/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.MannKind NASDAQ:MNKD$4.12 -0.10 (-2.37%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.15 +0.03 (+0.73%) As of 05/23/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Myriad Genetics NASDAQ:MYGN$3.91 -0.02 (-0.51%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.98 +0.07 (+1.79%) As of 05/23/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Novavax NASDAQ:NVAX$7.25 -0.04 (-0.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.20 -0.05 (-0.69%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
